TGTX Stock Analysis: TG Therapeutics | NASDAQ

Anti-CD20 Antibodies, BTK Inhibitors, Bispecific Antibodies

Total Rating 44

Safety 34

Buy Signal 0.48

Biotechnology
Industry Rotation: -4.2

Market Cap: 8.26B
Avg Turnover: 86.1M

Risk 3d forecast

Volatility51.0%

VaR 5^th Pctl7.65%

VaR vs Median-7.85%

Reward TTM

Sharpe Ratio1.10

Rel. Str. IBD91.5

Rel. Str. Peer Group76.8 pctl

Character TTM

Beta0.229

Beta Downside-0.680

Hurst Exponent0.494

Choppyness53.1%

Drawdowns 3y

Max DD42.01%

CAGR/Max DD2.28

CAGR/Mean DD5.58

EPS (Earnings per Share)

Last SUE: -3.59
Qual. Beats: -3

Revenue

Rev. CAGR: 62.95%
Rev. Trend: 97.3%

Last SUE: 2.18
Qual. Beats: 1

Warnings

Beneish M-Score Likely Earnings Manipulation

Tailwinds

Rs Leader

Idiosyncratic Leader

Seasonality 11.7 years of data

Jan +0.9% 17

Feb +3.4% 8

Mar +1.0% 17

Apr +0.4% 7

May -7.8% 28

Jun -3.1% 5

Jul -5.5% 20

Aug +4.8% 20

Sep -7.3% 27

Oct -5.6% 25

Nov +9.5% 38

Dec +7.7% 2

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: TGTX TG Therapeutics

TG Therapeutics, Inc. (NASDAQ: TGTX) is a commercial-stage biopharmaceutical company headquartered in Morrisville, North Carolina, that acquires, develops, and commercializes treatments for B-cell mediated diseases in the U.S. and international markets. The company markets BRIUMVI, an anti-CD20 monoclonal antibody approved for adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

Its clinical pipeline includes Ublituximab IV (an anti-CD20 mAb for relapsing MS), TG-1701 (an oral BTK inhibitor), and TG-1801 (a bispecific CD47/CD19 antibody), along with additional earlier-stage investigational programs. TG Therapeutics maintains license agreements with several partners, including LFB Biotechnologies, Ildong Pharmaceutical, and Jiangsu Hengrui Medicine, and has been listed on the Nasdaq since 1995.

Within the biotechnology sector, anti-CD20 monoclonal antibodies are a well-established class of therapies that target B-cells and are used across indications such as multiple sclerosis, lymphoma, and autoimmune diseases. BTK inhibitors represent a newer class of oral therapies with applications in both oncology and immune-mediated conditions, while CD47-targeted antibodies have drawn industry attention for their potential in immuno-oncology.

Headlines to Watch Out For

BRIUMVI sales growth drives revenue as MS market share expands
Competition intensifies from Ocrevus and Kesimpta in relapsing MS
Pipeline catalysts from TG-1701 BTK inhibitor and TG-1801 bispecific programs
Cash burn narrows as commercial-stage margins improve toward profitability

Piotroski VR-10 (Strict) 5.0

Net Income: 441.5m TTM > 0 and > 6% of Revenue
FCF/TA: 0.01 > 0.02 and ΔFCF/TA 9.49 > 1.0
NWC/Revenue: 109.7% < 20% (prev 108.4%; Δ 1.34% < -1%)
CFO/TA 0.01 > 3% & CFO 17.9m > Net Income 441.5m
Net Debt (211.2m) to EBITDA (134.3m): 1.57 < 3
Current Ratio: 4.27 > 1.5 & < 3
Outstanding Shares: last quarter (157.3m) vs 12m ago -3.25% < -2%
Gross Margin: 82.36% > 18% (prev 86.96%; Δ -4.59% > 0.5%)
Asset Turnover: 68.27% > 50% (prev 64.63%; Δ 3.65% > 0%)
Interest Coverage Ratio: 3.57 > 6 (EBIT TTM 134.0m / Interest Expense TTM 37.5m)

Altman Z'' 2.79

A: 0.53 (Total Current Assets 1.15b - Total Current Liabilities 268.5m) / Total Assets 1.64b
B: -0.64 (Retained Earnings -1.05b / Total Assets 1.64b)
C: 0.11 (EBIT TTM 134.0m / Avg Total Assets 1.17b)
D: 0.58 (Book Value of Equity 604.1m / Total Liabilities 1.04b)
Altman-Z'' = 2.79 = A

Beneish M 0.87

DSRI: 0.99 (Receivables 401.6m/231.5m, Revenue 799.5m/454.1m)
GMI: 1.06 (GM 86.96% / 82.36%)
AQI: 6.53 (AQ_t 0.30 / AQ_t-1 0.05)
SGI: 1.76 (Revenue 799.5m / 454.1m)
TATA: 0.26 (NI 441.5m - CFO 17.9m) / TA 1.64b)
Beneish M = 0.87 (Cap -4..+1) = D

What is the price of TGTX shares?

As of October 21, 2026, the stock is trading at USD 54.53 with a total of 1,056,168 shares traded. Over the past week, the price has changed by +0.35%, over one month by -4.60%, over three months by +1.06% and over the past year by +55.27%.

Current recommended Stop Loss: 50.10 (which is 8.1% or 2.1 ATR below the current price).

Is TGTX a buy, sell or hold?

TG Therapeutics has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy TGTX.

StrongBuy: 6
Buy: 1
Hold: 0
Sell: 1
StrongSell: 0

What are the forecasts/targets for the TGTX price?

Analysts Target Price	69.7	27.8%

TG Therapeutics (TGTX) - Fundamental Data Overview as of 18 October 2026

Market Cap USD = 8.26b (8.26b USD * 1.0 USD.USD)
P/E Trailing = 19.6255
P/E Forward = 25.9067
P/S = 10.3324
P/B = 14.1899
P/EG = 1.6144
Revenue TTM = 799.5m USD
EBIT TTM = 134.0m USD
EBITDA TTM = 134.3m USD
Long Term Debt = 745.4m USD (from longTermDebt, last quarter)
Short Term Debt = 1.91m USD (from shortTermDebt, last quarter)
Debt = 763.5m USD (from shortLongTermDebtTotal, last quarter) + Leases 9.05m
Net Debt = 211.2m USD (calculated: Debt 763.5m - CCE 552.2m)
Enterprise Value = 8.47b USD (8.26b + Debt 763.5m - CCE 552.2m)
Interest Coverage Ratio = 3.57 (Ebit TTM 134.0m / Interest Expense TTM 37.5m)
EV/FCF = 487.4x (Enterprise Value 8.47b / FCF TTM 17.4m)
FCF Yield = 0.21% (FCF TTM 17.4m / Enterprise Value 8.47b)
FCF Margin = 2.17% (FCF TTM 17.4m / Revenue TTM 799.5m)
Net Margin = 55.22% (Net Income TTM 441.5m / Revenue TTM 799.5m)
Gross Margin = 82.36% ((Revenue TTM 799.5m - Cost of Revenue TTM 141.0m) / Revenue TTM)
Gross Margin QoQ = 82.86% (prev 83.65%)
Tobins Q-Ratio = 5.17 (Enterprise Value 8.47b / Total Assets 1.64b)
Interest Expense / Debt = 4.91% (Interest Expense 37.5m / Debt 763.5m)
Taxrate = 23.97% (2.45m / 10.2m)
NOPAT = 101.9m (EBIT 134.0m * (1 - 23.97%))
Current Ratio = 4.27 (Total Current Assets 1.15b / Total Current Liabilities 268.5m)
Debt / Equity = 1.26 (Debt 763.5m / totalStockholderEquity, last quarter 604.1m)
Debt / EBITDA = 1.57 (Net Debt 211.2m / EBITDA 134.3m)
Debt / FCF = 12.15 (Net Debt 211.2m / FCF TTM 17.4m)
Total Stockholder Equity = 610.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 37.70% (Net Income 441.5m / Total Assets 1.64b)
RoE = 72.30% (Net Income TTM 441.5m / Total Stockholder Equity 610.6m)
RoCE = 9.88% (EBIT 134.0m / Capital Employed (Equity 610.6m + L.T.Debt 745.4m))
RoIC = 7.64% (NOPAT 101.9m / Invested Capital 1.33b)
WACC = 6.19% (E(8.26b)/V(9.03b) * Re(6.42%) + D(763.5m)/V(9.03b) * Rd(4.91%) * (1-Tc(0.24)))
Discount Rate = 6.42% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 38.39 | Cagr: 3.30%
[DCF] Terminal Value 75.44% ; FCFF base≈17.4m ; Y1≈17.5m ; Y5≈18.5m
[DCF] Fair Price = 0.50 (EV 287.6m - Net Debt 211.2m = Equity 76.4m / Shares 153.1m; r=8.35% [WACC [floored]]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -3.59 | # QB: -3
Revenue Correlation: 97.31 | Revenue CAGR: 62.95% | SUE: 2.18 | # QB: 1
EPS current Quarter (2026-09-30): EPS=0.26 | Chg30d=-21.49% | Revisions=-40% | Analysts=4
EPS current Year (2026-12-31): EPS=0.95 | Chg30d=+0.00% | Revisions=-50% | GrowthEPS=-65.7% | GrowthRev=+55.8%
EPS next Year (2027-12-31): EPS=2.71 | Chg30d=-8.67% | Revisions=+0% | GrowthEPS=+185.1% | GrowthRev=+37.4%
[Analyst] Revisions Ratio: -42% (up=2, down=7)